Literature DB >> 11202233

Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

J G Schoenecker1, R K Hauck, M C Mercer, W Parker, J H Lawson.   

Abstract

Exposure of humans to topical bovine thrombin has been associated with development of antibodies against bovine and human coagulation factors and blood coagulation abnormalities. However, the nature of this humoral response is unknown. In this study, numerous glycoproteins in the topical bovine thrombin were found to contain the Gal(alpha1)-3Gal epitope, which is known to be highly immunogenic. More importantly, Gal(alpha1)-3Gal is recognized by natural antibodies that are found in all normal individuals and are known to effectively mediate complement activation and subsequent destruction of xenogeneic tissues. Thus, primary exposure of normal individuals to topical bovine thrombin is expected to result in an immediate immune reaction against that reagent. Further, following exposure to topical bovine thrombin, the levels of anti-Gal(alpha1)-3Gal IgG rose to levels tenfold greater than the average level of natural anti-Gal(alpha1)-3Gal IgG in naive individuals. Thus, Gal(alpha1)-3Gal in topical bovine thrombin accounts for, at least in part, the highly immunogenic nature of this reagent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202233     DOI: 10.1023/a:1026455631876

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  63 in total

Review 1.  Tissue adhesives in cardiovascular surgery.

Authors:  U O von Oppell; P Zilla
Journal:  J Long Term Eff Med Implants       Date:  1998

Review 2.  Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images.

Authors:  B F Erlanger
Journal:  Int Rev Immunol       Date:  1989       Impact factor: 5.311

Review 3.  Controlled clinical studies of fibrin sealant in cardiothoracic surgery--a review.

Authors:  H K Kjaergard; J E Fairbrother
Journal:  Eur J Cardiothorac Surg       Date:  1996       Impact factor: 4.191

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Antibodies to topical bovine thrombin correlate with access thrombosis.

Authors:  J J Sands; S A Nudo; R G Ashford; K D Moore; T L Ortel
Journal:  Am J Kidney Dis       Date:  2000-05       Impact factor: 8.860

6.  Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.

Authors:  V D Chouhan; R A De La Cadena; C Nagaswami; J W Weisel; M Kajani; A K Rao
Journal:  Thromb Haemost       Date:  1997-02       Impact factor: 5.249

Review 7.  Molecular mimicry and the pathogenesis of insulin-dependent diabetes mellitus: still just an attractive hypothesis.

Authors:  M A Atkinson
Journal:  Ann Med       Date:  1997-10       Impact factor: 4.709

Review 8.  Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.

Authors:  T L Ortel; L A Charles; F G Keller; P K Marcom; H N Oldham; W H Kane; B G Macik
Journal:  Am J Hematol       Date:  1994-02       Impact factor: 10.047

9.  Risk and clinical significance of developing antibodies induced by topical thrombin preparations.

Authors:  R P Dorion; H F Hamati; B Landis; C Frey; D Heydt; D Carey
Journal:  Arch Pathol Lab Med       Date:  1998-10       Impact factor: 5.534

10.  The humoral immune response in humans following cross-perfusion of porcine organs.

Authors:  A H Cotterell; B H Collins; W Parker; R C Harland; J L Platt
Journal:  Transplantation       Date:  1995-10-27       Impact factor: 4.939

View more
  6 in total

1.  Exposure of mice to topical bovine thrombin induces systemic autoimmunity.

Authors:  J G Schoenecker; R K Johnson; A P Lesher; J D Day; S D Love; M R Hoffman; T L Ortel; W Parker; J H Lawson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 2.  Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.

Authors:  Steven A Berkowitz; John R Engen; Jeffrey R Mazzeo; Graham B Jones
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

Review 3.  Soft materials to treat central nervous system injuries: evaluation of the suitability of non-mammalian fibrin gels.

Authors:  Raivo Uibo; Ivo Laidmäe; Evelyn S Sawyer; Lisa A Flanagan; Penelope C Georges; Jessamine P Winer; Paul A Janmey
Journal:  Biochim Biophys Acta       Date:  2009-01-22

Review 4.  Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles.

Authors:  Mohammad A Alsenaidy; Nishant K Jain; Jae H Kim; C Russell Middaugh; David B Volkin
Journal:  Front Pharmacol       Date:  2014-03-12       Impact factor: 5.810

5.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

Review 6.  Biomaterials as Haemostatic Agents in Cardiovascular Surgery: Review of Current Situation and Future Trends.

Authors:  Horațiu Moldovan; Iulian Antoniac; Daniela Gheorghiță; Maria Sabina Safta; Silvia Preda; Marian Broască; Elisabeta Badilă; Oana Fronea; Alexandru Scafa-Udrişte; Mihai Cacoveanu; Adrian Molnar; Victor Sebastian Costache; Ondin Zaharia
Journal:  Polymers (Basel)       Date:  2022-03-16       Impact factor: 4.329

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.